Multiple Sclerosis Diagnostics Market Size, Share, and Trends 2026 to 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology 

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Multiple Sclerosis Diagnostics Market 

5.1. COVID-19 Landscape: Multiple Sclerosis Diagnostics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Multiple Sclerosis Diagnostics Market, By Diagnostic Type

8.1. Multiple Sclerosis Diagnostics Market, by Diagnostic Type

8.1.1. Magnetic Resonance Imaging (MRI)

8.1.1.1. Market Revenue and Forecast

8.1.2. Cerebrospinal Fluid (CSF) Analysis

8.1.2.1. Market Revenue and Forecast

8.1.3. Evoked Potential Testing

8.1.3.1. Market Revenue and Forecast

8.1.4. Blood-based Biomarker Testing

8.1.4.1. Market Revenue and Forecast

8.1.5. Optical Coherence Tomography (OCT)

8.1.5.1. Market Revenue and Forecast

8.1.6. Molecular & Genetic Diagnostics

8.1.6.1. Market Revenue and Forecast

Chapter 9. Global Multiple Sclerosis Diagnostics Market, By Biomarker Type

9.1. Multiple Sclerosis Diagnostics Market, by Biomarker Type

9.1.1. Neurofilament Light Chain (NfL)

9.1.1.1. Market Revenue and Forecast

9.1.2. Oligoclonal Bands (OCBs)

9.1.2.1. Market Revenue and Forecast

9.1.3. Glial Fibrillary Acidic Protein (GFAP)

9.1.3.1. Market Revenue and Forecast

9.1.4. Cytokine Biomarkers

9.1.4.1. Market Revenue and Forecast

9.1.5. Other Neurological Biomarkers

9.1.5.1. Market Revenue and Forecast

Chapter 10. Global Multiple Sclerosis Diagnostics Market, By Disease Type 

10.1. Multiple Sclerosis Diagnostics Market, by Disease Type

10.1.1. Relapsing-Remitting Multiple Sclerosis (RRMS)

10.1.1.1. Market Revenue and Forecast

10.1.2. Secondary Progressive Multiple Sclerosis (SPMS)

10.1.2.1. Market Revenue and Forecast

10.1.3. Primary Progressive Multiple Sclerosis (PPMS)

10.1.3.1. Market Revenue and Forecast

10.1.4. Progressive-Relapsing Multiple Sclerosis (PRMS)

10.1.4.1. Market Revenue and Forecast

Chapter 11. Global Multiple Sclerosis Diagnostics Market, By End-use

11.1. Multiple Sclerosis Diagnostics Market, by End-use

11.1.1. Hospitals

11.1.1.1. Market Revenue and Forecast

11.1.2. Diagnostic Laboratories

11.1.2.1. Market Revenue and Forecast

11.1.3. Specialty Neurology Clinics

11.1.3.1. Market Revenue and Forecast

11.1.4. Academic & Research Institutes

11.1.4.1. Market Revenue and Forecast

Chapter 12. Global Multiple Sclerosis Diagnostics Market, By Technology

12.1. Multiple Sclerosis Diagnostics Market, by Technology

12.1.1. Imaging Technologies

12.1.1.1. Market Revenue and Forecast

12.1.2. Immunoassays

12.1.2.1. Market Revenue and Forecast

12.1.3. Molecular Diagnostics

12.1.3.1. Market Revenue and Forecast

12.1.4. AI-based Diagnostic Analytics

12.1.4.1. Market Revenue and Forecast

Chapter 13. Global Multiple Sclerosis Diagnostics Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Diagnostic Type

13.1.2. Market Revenue and Forecast, by Biomarker Type

13.1.3. Market Revenue and Forecast, by Disease Type

13.1.4. Market Revenue and Forecast, by End-use

13.1.5. Market Revenue and Forecast, by Technology

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Diagnostic Type

13.1.6.2. Market Revenue and Forecast, by Biomarker Type

13.1.6.3. Market Revenue and Forecast, by Disease Type

13.1.6.4. Market Revenue and Forecast, by End-use

13.1.6.5. Market Revenue and Forecast, by Technology  

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Forecast, by Diagnostic Type

13.1.7.2. Market Revenue and Forecast, by Biomarker Type

13.1.7.3. Market Revenue and Forecast, by Disease Type

13.1.7.4. Market Revenue and Forecast, by End-use

13.1.7.5. Market Revenue and Forecast, by Technology

13.2. Europe

13.2.1. Market Revenue and Forecast, by Diagnostic Type

13.2.2. Market Revenue and Forecast, by Biomarker Type

13.2.3. Market Revenue and Forecast, by Disease Type

13.2.4. Market Revenue and Forecast, by End-use  

13.2.5. Market Revenue and Forecast, by Technology  

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Diagnostic Type

13.2.6.2. Market Revenue and Forecast, by Biomarker Type

13.2.6.3. Market Revenue and Forecast, by Disease Type

13.2.7. Market Revenue and Forecast, by End-use  

13.2.8. Market Revenue and Forecast, by Technology  

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Diagnostic Type

13.2.9.2. Market Revenue and Forecast, by Biomarker Type

13.2.9.3. Market Revenue and Forecast, by Disease Type

13.2.10. Market Revenue and Forecast, by End-use

13.2.11. Market Revenue and Forecast, by Technology

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Diagnostic Type

13.2.12.2. Market Revenue and Forecast, by Biomarker Type

13.2.12.3. Market Revenue and Forecast, by Disease Type

13.2.12.4. Market Revenue and Forecast, by End-use

13.2.13. Market Revenue and Forecast, by Technology

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Diagnostic Type

13.2.14.2. Market Revenue and Forecast, by Biomarker Type

13.2.14.3. Market Revenue and Forecast, by Disease Type

13.2.14.4. Market Revenue and Forecast, by End-use

13.2.15. Market Revenue and Forecast, by Technology

13.3. APAC

13.3.1. Market Revenue and Forecast, by Diagnostic Type

13.3.2. Market Revenue and Forecast, by Biomarker Type

13.3.3. Market Revenue and Forecast, by Disease Type

13.3.4. Market Revenue and Forecast, by End-use

13.3.5. Market Revenue and Forecast, by Technology

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Diagnostic Type

13.3.6.2. Market Revenue and Forecast, by Biomarker Type

13.3.6.3. Market Revenue and Forecast, by Disease Type

13.3.6.4. Market Revenue and Forecast, by End-use

13.3.7. Market Revenue and Forecast, by Technology

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Diagnostic Type

13.3.8.2. Market Revenue and Forecast, by Biomarker Type

13.3.8.3. Market Revenue and Forecast, by Disease Type

13.3.8.4. Market Revenue and Forecast, by End-use

13.3.9. Market Revenue and Forecast, by Technology

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Diagnostic Type

13.3.10.2. Market Revenue and Forecast, by Biomarker Type

13.3.10.3. Market Revenue and Forecast, by Disease Type

13.3.10.4. Market Revenue and Forecast, by End-use

13.3.10.5. Market Revenue and Forecast, by Technology

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Diagnostic Type

13.3.11.2. Market Revenue and Forecast, by Biomarker Type

13.3.11.3. Market Revenue and Forecast, by Disease Type

13.3.11.4. Market Revenue and Forecast, by End-use

13.3.11.5. Market Revenue and Forecast, by Technology

13.4. MEA

13.4.1. Market Revenue and Forecast, by Diagnostic Type

13.4.2. Market Revenue and Forecast, by Biomarker Type

13.4.3. Market Revenue and Forecast, by Disease Type

13.4.4. Market Revenue and Forecast, by End-use

13.4.5. Market Revenue and Forecast, by Technology

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Diagnostic Type

13.4.6.2. Market Revenue and Forecast, by Biomarker Type

13.4.6.3. Market Revenue and Forecast, by Disease Type

13.4.6.4. Market Revenue and Forecast, by End-use

13.4.7. Market Revenue and Forecast, by Technology

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Diagnostic Type

13.4.8.2. Market Revenue and Forecast, by Biomarker Type

13.4.8.3. Market Revenue and Forecast, by Disease Type

13.4.8.4. Market Revenue and Forecast, by End-use

13.4.9. Market Revenue and Forecast, by Technology

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Diagnostic Type

13.4.10.2. Market Revenue and Forecast, by Biomarker Type

13.4.10.3. Market Revenue and Forecast, by Disease Type

13.4.10.4. Market Revenue and Forecast, by End-use

13.4.10.5. Market Revenue and Forecast, by Technology

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Diagnostic Type

13.4.11.2. Market Revenue and Forecast, by Biomarker Type

13.4.11.3. Market Revenue and Forecast, by Disease Type

13.4.11.4. Market Revenue and Forecast, by End-use

13.4.11.5. Market Revenue and Forecast, by Technology

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Diagnostic Type

13.5.2. Market Revenue and Forecast, by Biomarker Type

13.5.3. Market Revenue and Forecast, by Disease Type

13.5.4. Market Revenue and Forecast, by End-use

13.5.5. Market Revenue and Forecast, by Technology

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Diagnostic Type

13.5.6.2. Market Revenue and Forecast, by Biomarker Type

13.5.6.3. Market Revenue and Forecast, by Disease Type

13.5.6.4. Market Revenue and Forecast, by End-use

13.5.7. Market Revenue and Forecast, by Technology

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Diagnostic Type

13.5.8.2. Market Revenue and Forecast, by Biomarker Type

13.5.8.3. Market Revenue and Forecast, by Disease Type

13.5.8.4. Market Revenue and Forecast, by End-use

13.5.8.5. Market Revenue and Forecast, by Technology

Chapter 14. Company Profiles

14.1. F. Hoffmann-La Roche Ltd.

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Siemens Healthineers

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. GE HealthCare

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Thermo Fisher Scientific

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Qiagen N.V.

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Abbott Laboratories

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Danaher Corporation

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Philips Healthcare

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Canon Medical Systems

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Bio-Rad Laboratories

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms